JPH0262826A - Remedy for adult t-cell leukemia - Google Patents
Remedy for adult t-cell leukemiaInfo
- Publication number
- JPH0262826A JPH0262826A JP21575388A JP21575388A JPH0262826A JP H0262826 A JPH0262826 A JP H0262826A JP 21575388 A JP21575388 A JP 21575388A JP 21575388 A JP21575388 A JP 21575388A JP H0262826 A JPH0262826 A JP H0262826A
- Authority
- JP
- Japan
- Prior art keywords
- adult
- compound
- bond
- remedy
- cell leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 title claims abstract description 10
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 title claims abstract description 10
- 201000006966 adult T-cell leukemia Diseases 0.000 title claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 4
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 150000005053 phenanthridines Chemical class 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 238000010253 intravenous injection Methods 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- PZMWVPMSNYHCPK-UHFFFAOYSA-N ethyl n-[3-(ethoxycarbonylamino)-5-ethyl-6-phenylphenanthridin-5-ium-8-yl]carbamate;bromide Chemical compound [Br-].C=1C(NC(=O)OCC)=CC=C(C2=CC=C(NC(=O)OCC)C=C2[N+]=2CC)C=1C=2C1=CC=CC=C1 PZMWVPMSNYHCPK-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000001668 nucleic acid synthesis Methods 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- -1 1so-propyl Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Landscapes
- Other In-Based Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はフェナンスリジン誘導体を有効成分とする成人
Ｔ細胞白血病（ＡＴＬ）の治療剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a therapeutic agent for adult T-cell leukemia (ATL) containing a phenanthridine derivative as an active ingredient.
〔従来技術・発明が解決しようとする課題〕後記一般式
（１）で表される化合物は核酸合成阻害作用を存しくＪ
、 Ｍｏ１． Ｒｉｏｔ、、 １３．２６９ （１９
６５）〕、強い抗菌力を存することが知られている。[Prior art/problems to be solved by the invention] The compound represented by the general formula (1) below has a nucleic acid synthesis inhibiting effect.
, Mo1. Riot,, 13.269 (19
65)] is known to have strong antibacterial activity.
−１式（１）で表される化合物はこのような薬理作用を
有する化合物ではあるが、臨床使用を可能とする作用は
見出されておらず、実験段階でとどまっている。Although the compound represented by the -1 formula (1) has such a pharmacological effect, no effect that would enable clinical use has been found and it remains at the experimental stage.
１課題を解決するための手段］
そこで本発明者らは一般式（１）で表される化合物の薬
理作用について研究を重ねてきたところ、当該化合物が
ＡＴＬに有効であることを見出し、本発明を完成した。[Means for Solving Problem 1] The present inventors have conducted repeated research on the pharmacological action of the compound represented by the general formula (1), and found that the compound is effective against ATL. completed.
即ち、本発明は一般式
％式％）
（式中、Ｒ１は低級アルキルを、Ｒ２およびＲ３は同一
または異なってアルカノイルもしくはアルコキシカルボ
ニルを、Ｘはハロゲン原子を、ニーは単結合または二重
結合を示す。ただしユニが単結合のときはＸは存在しな
い。）
で表されるフェナンスリジン誘導体を有効成分とする成
人下細胞白血病治療剤である。That is, the present invention is based on the general formula %) (wherein, R1 represents lower alkyl, R2 and R3 are the same or different and represent alkanoyl or alkoxycarbonyl, X represents a halogen atom, and N represents a single bond or a double bond. However, when Uni is a single bond, X is not present.
本明細書中で、Ｒ１における低級アルキルは、好ましく
は炭素数１〜４の低級アルキルであり、たとえばメチル
、エチル、プロピル、１ｓｏ−プロピル、ブチル、【−
ブチル、１ｓｏ−ブチルなどが例示される。In the present specification, the lower alkyl in R1 is preferably lower alkyl having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 1so-propyl, butyl, [-
Examples include butyl and 1so-butyl.
Ｒ２、Ｒ３におけるアルカノイルとしてはアセチル、プ
ロピオニル等の炭素数２〜５のアルカノイルが例示され
る。Examples of alkanoyl in R2 and R3 include alkanoyl having 2 to 5 carbon atoms such as acetyl and propionyl.
Ｒ１、Ｒ５におけるアルコキシカルボニルのアルコキシ
としてはメトキシ、エトキシ、プロポキシなどの炭素数
１〜４のアルコキシが例示される。Examples of the alkoxy in the alkoxycarbonyl in R1 and R5 include alkoxy having 1 to 4 carbon atoms such as methoxy, ethoxy, and propoxy.
Ｘで表されるハロゲン原子としては塩素、臭素、ヨウ素
などが例示される。Examples of the halogen atom represented by X include chlorine, bromine, and iodine.
一般式Ｎ）で表される化合物として、たとえば３，８−
ジー（エトキシカルボニルアミノ）−５エチル−６−フ
エニルフエナンスリジニウムブロマイド（以下に−４と
略する） 、３．８−ジー（プロピオニルアミノ）−５
−エチル−６−フエニルフエナンスリジニウムブロマイ
ド（以下に−５と略する） 、３．８−ジー（プロピオ
ニルアミノ）−５−エチル−６Ｈ−６−フェニルフェナ
ンスリジン（以下に−６と略する）などの化合物が例示
される。As a compound represented by the general formula N), for example, 3,8-
Di(ethoxycarbonylamino)-5ethyl-6-phenylphenanthridinium bromide (hereinafter abbreviated as -4), 3,8-di(propionylamino)-5
-ethyl-6-phenylphenanthridinium bromide (hereinafter abbreviated as -5), 3,8-di(propionylamino)-5-ethyl-6H-6-phenylphenanthridine (hereinafter abbreviated as -6) (abbreviated)) are exemplified.
一般式（１）で表される化合物はＪ、 Ｔ、門ＡＣＧＲ
−ＥＧＯＲら（ＢｉｏｃｈｅＩＩｌｉｃａｌ Ｐｈａｒ
ｍａｃｏｌｏｇｙ、 別、 ２８３３ （１９７１）
）および−、Ｊ、 Ｆｉｒｔｈら（Ｊ、 Ｈｅｔｅｒｏ
ｃｙｃｌｉｃｃｈｅｍｉｓＬｒｙ、 ２０．７５９ （
１９８３））の方法に準じて製造することができる。The compound represented by the general formula (1) is J, T, ACGR
-EGOR et al. (BiocheIIlical Phar
Macology, Separate, 2833 (1971)
) and -, J, Firth et al. (J, Hetero
cyclicchemisLry, 20.759 (
1983)).
ＨＴ Ｌ Ｖ （ｈｕｍａｎ Ｔ ｃｅｌｌ
ｌｅｕｋｅｍｉａ ｖ、ｔｒｕｓ） −１はＡＴＬ
発癌の直接的な原因といわれており、ＨＴＬＶ−１に対
する有効性が示されれば、その化合物はＡＴＬ治療剤と
して有効である。そこで下記実験例に示すように、−数
式（１）で表される化合物についてのＨＴＬＶ−１に対
する作用を調べ、当該化合物がｎＴｔ、ｖ−ｔに対して
有効であり、かつ細胞毒性の弱いことが見出された。HT L V (human T cell
leukemia v, trus) -1 is ATL
It is said to be a direct cause of carcinogenesis, and if efficacy against HTLV-1 is demonstrated, the compound will be effective as a therapeutic agent for ATL. Therefore, as shown in the experimental example below, we investigated the effect of the compound represented by formula (1) on HTLV-1 and found that the compound is effective against nTt and vt and has weak cytotoxicity. was discovered.
なお、各実験例におけるＨＴＬＶ−１の抗原発現量の測
定方法は以下の通りである。The method for measuring the amount of HTLV-1 antigen expression in each experimental example is as follows.
所定濃度の試験薬剤存在下でＨＴＬＶ−１陽性ＭＴ−４
細胞を培養し、３日および５日目に間接蛍光抗体法によ
りＨＴＬＶ−１の抗原発現量を測定した。HTLV-1 positive MT-4 in the presence of a given concentration of test drug
The cells were cultured, and the amount of HTLV-1 antigen expression was measured by indirect fluorescent antibody method on the 3rd and 5th day.
実験例Ｉ
ＨＴＬＶ−１陽性ＭＴ−４細胞にに−４、Ｋ−５または
に−６をそれぞれ１０−’Ｍ、１０−’Ｍまたは１０−
’Ｍ濃度となるように加えて培養し、３日目および５日
目に間接蛍光抗体法によりＨＴＬＶ−１の抗原発現量の
測定を行った。即ち、ｌ−Ｉ ＴＬＶ−１陽性ＭＴ−４
細胞をスライドグラスに固定した後、ＨＴＬＶ−１抗体
陽性者血清と３７°Ｃで３０分間反応させた。続いて蛍
光物質を標識したヒトＩｇＧ抗体を同様に反応させた後
、蛍光顕微鏡下で観察して抗原陽性細胞を数え、ＨＴＬ
Ｖ−１抗原発現率を算定した。その結果を初期値との比
率（％）にて表し、第１図に示す。Experimental Example I HTLV-1 positive MT-4 cells were treated with Ni-4, K-5 or Ni-6 at 10-'M, 10-'M or 10-'M, respectively.
'M concentration and cultured, and on the 3rd and 5th day, the amount of HTLV-1 antigen expression was measured by indirect fluorescent antibody method. That is, l-I TLV-1 positive MT-4
After fixing the cells on a glass slide, they were reacted with serum from a positive HTLV-1 antibody at 37°C for 30 minutes. Next, human IgG antibodies labeled with a fluorescent substance were reacted in the same manner, and then observed under a fluorescence microscope to count antigen-positive cells.
V-1 antigen expression rate was calculated. The results are expressed as a ratio (%) to the initial value and are shown in FIG.
第１図に示した結果から明らかなように、−数式（１）
で表される化合物、特にに−４はＨＴＬＶ−１に対する
成人Ｔ細胞白血病ウィルスの情報発現を抑制する効果が
見られた。As is clear from the results shown in Figure 1, −Equation (1)
The compound represented by, especially Ni-4, was found to be effective in suppressing the expression of adult T-cell leukemia virus information against HTLV-1.
実験例２
正常ＭＴ−４細胞（細胞数１×１０Ｓ個）にに−４、Ｋ
−５またはに−６を、それぞれ１０−’Ｍ、１０−’Ｍ
、１０−５Ｍまたはｌ Ｏ−’Ｍ１度トナルヨうに加え
て培養し、３日目あるいは５日目にＭＴ−４細胞数を数
えた。その結果を第２図に示す。Experimental Example 2 -4, K to normal MT-4 cells (1 x 10S cells)
-5 or -6 to 10-'M, 10-'M respectively
, 10-5M or 1 O-'M and cultured, and the number of MT-4 cells was counted on the 3rd or 5th day. The results are shown in FIG.
本発明治療剤は、治療上有効な量の一般式（］）で表さ
れる化合物と、必要に応じて、薬理学的に許容される賦
形剤または添加剤（たとえば、希釈剤、充填剤、乳化剤
、潤滑剤、香料または着色剤等の添加剤）とを混合し、
適当な剤型（たとえば、錠剤、糖衣剤、カプセル剤等の
経口剤、注射剤、坐剤、外用剤等の非経口剤）とするこ
とによって製造される。The therapeutic agent of the present invention contains a therapeutically effective amount of the compound represented by the general formula (]) and, if necessary, a pharmacologically acceptable excipient or additive (e.g., diluent, filler). , emulsifiers, lubricants, additives such as fragrances or colorants),
It is manufactured by forming it into an appropriate dosage form (for example, oral preparations such as tablets, sugar-coated agents, and capsules, and parenteral preparations such as injections, suppositories, and external preparations).
本発明治療剤は、たとえば経口的、または非経口的に投
与される。特に好ましい投与ルートは、経口投与、静脈
注射、直腸投与である。The therapeutic agent of the present invention is administered, for example, orally or parenterally. Particularly preferred routes of administration are oral administration, intravenous injection, and rectal administration.
本発明治療剤には、−数式（１）で表される化合物以外
の他の制癌剤、たとえば免疫療法剤（ビシハニー ＪＬ
／ 類、クレスチン類、インターフェロン類、リンホカ
イン類等）または全身的な症状の治療剤（解熱剤、鎮痛
剤、消炎剤等）を併用してもよい。The therapeutic agent of the present invention includes - other anticancer agents other than the compound represented by formula (1), such as an immunotherapeutic agent (Visihoney JL
/ Krestins, interferons, lymphokines, etc.) or therapeutic agents for systemic symptoms (antipyretics, analgesics, anti-inflammatory drugs, etc.) may be used in combination.
本発明治療剤の投与量は症状、体重、年令、投与方法等
によって変わるが、一般式Ｎ）で表される化合物として
一般に成人に対して、静脈内投与の場合１日あたり１０
μｇ〜１０００■、好ましくはｌＯＯμｇ〜１００■を
１回または数回に分けて投与される。Although the dosage of the therapeutic agent of the present invention varies depending on the symptoms, body weight, age, administration method, etc., the compound represented by the general formula N) is generally administered to adults at 100 mg/day when administered intravenously.
The dose is 100 μg to 1000 μg, preferably 100 μg to 100 μg, administered once or divided into several doses.
実施例１
有効成分 ２０■微品性セルロー
ス ２５■ヒドロキシプロピルセルロース
１■カルボキシメチルセルロース
カルシウム ５■ステアリン酸マ
グネシウム ２ｍｇ乳糖 適量を加えて全量１５
０■とする。Example 1 Active ingredients 20■Microcellulose 25■Hydroxypropyl cellulose 1■Carboxymethyl cellulose calcium 5■Magnesium stearate 2mg Lactose Add appropriate amount to make total amount 15
Set to 0■.
上記成分を混合し、湿式法により造粒し、打錠し、常法
により糖衣を施す。The above ingredients are mixed, granulated by a wet method, compressed into tablets, and coated with sugar by a conventional method.
実施例２
有効成分 ５０■生理食塩水 適
量を加えて全Ｎ１０−とする。Example 2 Active ingredient 50 ■ Physiological saline Add appropriate amount to make total N10-.
第１図は一般式（１）で表される化合物のＨＴＬＶ−１
に対する成人Ｔ細胞白血病ウィルスの情報発現を抑制す
る効果を調べたグラフである。
第２図は一般式（１）で表される化合物を添加、培養し
た際の細胞生存率を示すグラフである。
第１図中の各棒グラフはそれぞれ次のものを意味する。
口・・・コントロール
Ｚ・・・１０−６
塁・・・１０−ｓ
口・・・１０−４
第２図中の各シンボルはそれぞれ次のものを意味する。
・・・・コントロール
・・・１０−’
○・・・１０−６
０・・・１０−’
Δ・・・１０−４Figure 1 shows HTLV-1 of the compound represented by general formula (1).
It is a graph examining the effect of suppressing the information expression of adult T cell leukemia virus on. FIG. 2 is a graph showing the cell survival rate when the compound represented by general formula (1) was added and cultured. Each bar graph in FIG. 1 means the following. Mouth: Control Z: 10-6 Base: 10-s Mouth: 10-4 Each symbol in Figure 2 means the following. ...Control...10-' ○...10-6 0...10-' Δ...10-4
Claims (1)
は同一または異なってアルカノイルもしくはアルコキシ
カルボニルを、Ｘはハロゲン原子を、■は単結合または
二重結合を示す。ただし■が単結合のときはＸは存在し
ない。） で表されるフェナンスリジン誘導体を有効成分とする成
人Ｔ細胞白血病治療剤。[Claims] General formula ▲ Numerical formula, chemical formula, table, etc. ▼ (In the formula, R^1 is lower alkyl, R^2 and R^3
are the same or different and represent alkanoyl or alkoxycarbonyl, X represents a halogen atom, and ■ represents a single bond or a double bond. However, when ■ is a single bond, X does not exist. ) A therapeutic agent for adult T-cell leukemia, which contains a phenanthridine derivative represented by the following as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21575388A JPH0262826A (en) | 1988-08-30 | 1988-08-30 | Remedy for adult t-cell leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21575388A JPH0262826A (en) | 1988-08-30 | 1988-08-30 | Remedy for adult t-cell leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0262826A true JPH0262826A (en) | 1990-03-02 |
Family
ID=16677652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21575388A Pending JPH0262826A (en) | 1988-08-30 | 1988-08-30 | Remedy for adult t-cell leukemia |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0262826A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502745A (en) * | 2002-10-18 | 2006-01-26 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク | Screening kit for molecules having anti-prion activity, screening method for molecules having anti-prion activity, and screened molecules |
| CN105001665A (en) * | 2014-04-15 | 2015-10-28 | 苏州嘉恒生物科技有限公司 | Preparation and applications of novel nucleic acid dye |
-
1988
- 1988-08-30 JP JP21575388A patent/JPH0262826A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502745A (en) * | 2002-10-18 | 2006-01-26 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク | Screening kit for molecules having anti-prion activity, screening method for molecules having anti-prion activity, and screened molecules |
| CN105001665A (en) * | 2014-04-15 | 2015-10-28 | 苏州嘉恒生物科技有限公司 | Preparation and applications of novel nucleic acid dye |
| CN105001665B (en) * | 2014-04-15 | 2017-05-31 | 苏州嘉恒生物科技有限公司 | The preparation and its application of a kind of new nucleic acid dyestuff |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU593051B2 (en) | Method of treating alzheimer's disease | |
| AU654555B2 (en) | Composition, method and kit for potentiating antitumor activity and for curing tumor | |
| TWI302836B (en) | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity | |
| EP3672591B1 (en) | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop | |
| JPH02256700A (en) | Cytotoxic drug conjugate | |
| RU2145849C1 (en) | Use of acylfulven analogs and pharmaceutical composition based on thereof | |
| CA2276525A1 (en) | Substituted bis-acridines and related compounds as ccr5 receptor ligands, anti-inflammatory agents and anti-viral agents | |
| JPH05503721A (en) | Bis-(hydroxyalkylamino)-anthraquinone inhibitor of protein kinase C | |
| JPH10511080A (en) | Use of halogenated aromatics to treat mammalian cell proliferation | |
| EP0565519B1 (en) | Illudin analogs as anti-tumor agents | |
| JPH07277982A (en) | Mdr-resistant medical treatment | |
| JPH0296523A (en) | Platinum chemical remedy product | |
| JPS6064927A (en) | Composition for treatment and diagnostics | |
| JPH0262826A (en) | Remedy for adult t-cell leukemia | |
| US11453664B2 (en) | Thymoquinone/harmaline and related reaction products | |
| JP5170940B2 (en) | Composition containing high purity amphotericin B | |
| JPS6185320A (en) | Enhancer for effect of antitumor agent | |
| Smal et al. | Drugs as allergens: The molecular basis of IgE binding to trimethoprim | |
| JPH04338328A (en) | Benzoylcarbinol and its ester useful as blood vessel formation inhibitors | |
| JPS58159410A (en) | Anti-inflammatory | |
| JPH02121923A (en) | Cancer treatment for mammal under simultaneous dosage of 4-quinoline carboxylic acid delivative and interleukin-2 | |
| US5272159A (en) | Adjuncts in cancer chemotherapy | |
| Lennard et al. | Timolol metabolism and debrisoquine oxidation polymorphism: a population study. | |
| JP2767176B2 (en) | Anticancer drug | |
| US3515788A (en) | Anti-tubercular compositions and methods employing pyridine derivatives |